Literature DB >> 6871116

Effects of chronic exposure to arsenate on the cardiovascular function of rats.

M Carmignani, P Boscolo, A Iannaccone.   

Abstract

Cardiovascular function was studied in anaesthetised male rats which received 50 micrograms/ml of arsenic (as sodium arsenate) in deionised drinking water for 320 days. High urinary excretion of arsenic was found at the end of treatment and the metal accumulated considerably in the kidneys and liver, which both presented slight alterations. No histopathological modifications were evident in other organs. Base line blood pressure, cardiac inotropism, and chronotropism and cardiovascular reactivity to noradrenaline, acetylcholine, angiotensin II, bradykinin, histamine, and serotonin did not differ in exposed or in control animals. In the exposed group, however, there was potentiation of the effects of vascular beta-adrenoceptor stimulation and a reduction in the vascular responsiveness to angiotensin I. Chronic arsenic exposure did not affect the baroreflex sensitivity but was able to induce sympathetic hyperactivity or hypersensitivity, or both, possibly associated with an antivagal action. Our results might help to explain the cardiovascular alterations seen in people chronically exposed to high concentrations of arsenic.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6871116      PMCID: PMC1069323          DOI: 10.1136/oem.40.3.280

Source DB:  PubMed          Journal:  Br J Ind Med        ISSN: 0007-1072


  18 in total

1.  INTERRELATIONS OF ARSENATE AND PHOSPHATE TRANSPORT IN THE DOG KIDNEY.

Authors:  J M GINSBURG; W D LOTSPEICH
Journal:  Am J Physiol       Date:  1963-10

2.  The electrocardiogram in acute arsenic poisoning.

Authors:  S L WEINBERG
Journal:  Am Heart J       Date:  1960-12       Impact factor: 4.749

3.  [Experimental studies on the ECG changes in chronic arsenic poisoning].

Authors:  W MASSMANN; H OPITZ
Journal:  Z Kreislaufforsch       Date:  1954-10

4.  Atomic absorption determination of nanogram quantities of arsenic in biological media.

Authors:  R M Orheim; H H Bovee
Journal:  Anal Chem       Date:  1974-06       Impact factor: 6.986

5.  [Epidemiologic study of arsenic poisoning in the city of Antofagasta].

Authors:  J M Borgoño; R Greiber
Journal:  Rev Med Chil       Date:  1971-09       Impact factor: 0.553

6.  Electrocardiographic findings with arsenic poisoning.

Authors:  F S Glazener; J G Ellis; P K Johnson
Journal:  Calif Med       Date:  1968-08

7.  Arsenic and respiratory cancer in man: an occupational study.

Authors:  A M Lee; J F Fraumeni
Journal:  J Natl Cancer Inst       Date:  1969-06       Impact factor: 13.506

8.  Mortality experience of arsenic-exposed workers.

Authors:  S S Pinto; V Henderson; P E Enterline
Journal:  Arch Environ Health       Date:  1978 Nov-Dec

9.  Arsenic exposure and mortality: a case-referent study from a Swedish copper smelter.

Authors:  O Axelson; E Dahlgren; C D Jansson; S O Rehnlund
Journal:  Br J Ind Med       Date:  1978-02

10.  [Coronary occlusions associated with chronic arsenic poisoning. Apropos of 2 operated cases].

Authors:  S Moran; G Maturana; H Rosenberg; P Casanegra; J Dubernet
Journal:  Arch Mal Coeur Vaiss       Date:  1977-10
View more
  3 in total

1.  Neovascularization and angiogenic gene expression following chronic arsenic exposure in mice.

Authors:  Nicole V Soucy; Debra Mayka; Linda R Klei; Antonia A Nemec; John A Bauer; Aaron Barchowsky
Journal:  Cardiovasc Toxicol       Date:  2005       Impact factor: 3.231

2.  Non-carcinogenic effects of inorganic arsenic.

Authors:  C O Abernathy; E V Ohanian
Journal:  Environ Geochem Health       Date:  1992-06       Impact factor: 4.609

3.  Blood pressure hyperreactivity: an early cardiovascular risk in normotensive men exposed to low-to-moderate inorganic arsenic in drinking water.

Authors:  Julie Kunrath; Eugen Gurzau; Anca Gurzau; Walter Goessler; Elyssa R Gelmann; Thu-Trang Thach; Kathleen M McCarty; Catherine W Yeckel
Journal:  J Hypertens       Date:  2013-02       Impact factor: 4.844

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.